ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.620
-0.040 (-2.41%)
Jan 10, 2025, 4:00 PM EST - Market closed
Company Description
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Bruce Culleton |
Contact Details
Address: 2000 Frontis Plaza Blvd., Suite 250 Winston-Salem, North Carolina 27103 United States | |
| Phone | 336 999 7028 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| ISIN Number | KYG7S53R1049 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer and Director |
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder |
| James Coulston CPA | Chief Financial Officer |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer and Secretary |
| Anu Biswas | Senior Vice President of Manufacturing and Operations |
| Dr. Ulrich Ernst Ph.D. | Executive Vice President of Science and Technology |
| Carla Poulson | Chief People Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access |
| Nikhil L. Pereira-Kamath | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 19, 2024 | 144 | Filing |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |